Johan Bratt

1.9k total citations
38 papers, 1.4k citations indexed

About

Johan Bratt is a scholar working on Rheumatology, Immunology and Genetics. According to data from OpenAlex, Johan Bratt has authored 38 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Rheumatology, 20 papers in Immunology and 7 papers in Genetics. Recurrent topics in Johan Bratt's work include Rheumatoid Arthritis Research and Therapies (17 papers), Neutrophil, Myeloperoxidase and Oxidative Mechanisms (11 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Johan Bratt is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (17 papers), Neutrophil, Myeloperoxidase and Oxidative Mechanisms (11 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Johan Bratt collaborates with scholars based in Sweden, United States and Netherlands. Johan Bratt's co-authors include Sofia Ernestam, Ronald van Vollenhoven, Ingemar F. Petersson, Pierre Geborek, Jan Palmblad, Kristina Forslind, Katerina Chatzidionysiou, Kristina Albertsson, Saedís Saevarsdóttir and Helena Wallin and has published in prestigious journals such as The Lancet, The Journal of Immunology and Annals of the New York Academy of Sciences.

In The Last Decade

Johan Bratt

34 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Johan Bratt Sweden	21	952	393	370	290	197	38	1.4k
Maria Seddighzadeh Sweden	20	695 0.7×	403 1.0×	191 0.5×	223 0.8×	168 0.9×	35	1.4k
Sergio Schwartzman United States	21	955 1.0×	548 1.4×	398 1.1×	127 0.4×	163 0.8×	59	1.4k
Kentaro Hanami Japan	18	768 0.8×	311 0.8×	218 0.6×	156 0.5×	165 0.8×	53	1.2k
Marek Brzosko Poland	20	916 1.0×	633 1.6×	261 0.7×	119 0.4×	185 0.9×	124	1.6k
Agata Burska United Kingdom	21	602 0.6×	318 0.8×	137 0.4×	221 0.8×	135 0.7×	66	1.4k
Jacques‐Eric Gottenberg France	20	961 1.0×	328 0.8×	324 0.9×	248 0.9×	185 0.9×	58	1.5k
Floranne C. Ernste United States	21	810 0.9×	390 1.0×	138 0.4×	141 0.5×	186 0.9×	50	1.4k
Iván Ferraz‐Amaro Spain	20	916 1.0×	396 1.0×	208 0.6×	82 0.3×	157 0.8×	144	1.5k
C. Gaich United States	16	1.3k 1.4×	459 1.2×	662 1.8×	360 1.2×	199 1.0×	40	1.9k
K. H. Han Netherlands	10	1.6k 1.6×	243 0.6×	633 1.7×	355 1.2×	252 1.3×	16	1.8k

Countries citing papers authored by Johan Bratt

Since Specialization

Citations

This map shows the geographic impact of Johan Bratt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan Bratt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan Bratt more than expected).

Fields of papers citing papers by Johan Bratt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johan Bratt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan Bratt. The network helps show where Johan Bratt may publish in the future.

Co-authorship network of co-authors of Johan Bratt

This figure shows the co-authorship network connecting the top 25 collaborators of Johan Bratt. A scholar is included among the top collaborators of Johan Bratt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johan Bratt. Johan Bratt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heijde, Désirée van der, Maxime Bréban, D Halter, et al.. (2014). Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. Lara D. Veeken. 54(7). 1210–1219. 42 indexed citations

Eriksson, Jonas, Johan Karlsson, Johan Bratt, et al.. (2014). Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. Annals of the Rheumatic Diseases. 74(6). 1094–1101. 43 indexed citations

Andersson, Patrik, et al.. (2014). Inhibition of Neutrophil‐Dependent Cytotoxicity for Human Endothelial Cells by ACE Inhibitors. Scandinavian Journal of Immunology. 80(5). 339–345. 3 indexed citations

Eriksson, Jonas, Martin Neovius, Johan Bratt, et al.. (2013). Biological vs Conventional Combination Treatment and Work Loss in Early Rheumatoid Arthritis. JAMA Internal Medicine. 173(15). 1407–1407. 29 indexed citations

Börjesson, Ola, Johan Bratt, Björn Anderstam, et al.. (2013). Macrophage Migration Inhibitory Factor (MIF) and Thyroid Hormone Alterations in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV). Molecular Medicine. 19(1). 109–114. 9 indexed citations

Karlsson, Johan, Martin Neovius, Jan‐Åke Nilsson, et al.. (2012). Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. Annals of the Rheumatic Diseases. 72(12). 1927–1933. 21 indexed citations

Vollenhoven, Ronald van, Pierre Geborek, Kristina Forslind, et al.. (2012). Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. The Lancet. 379(9827). 1712–1720. 157 indexed citations

Saevarsdóttir, Saedís, Kristina Forslind, Kristina Albertsson, et al.. (2011). In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Annals of the Rheumatic Diseases. 71(2). 186–191. 75 indexed citations

Saevarsdóttir, Saedís, Helena Wallin, Maria Seddighzadeh, et al.. (2010). Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Annals of the Rheumatic Diseases. 70(3). 469–475. 149 indexed citations

10.

Bruchfeld, Annette, Johan Bratt, Abdul Rashid Qureshi, et al.. (2010). High-Mobility Group Box-1 Protein (HMGB1) Is Increased in Antineutrophilic Cytoplasmatic Antibody (ANCA)-Associated Vasculitis with Renal Manifestations. Molecular Medicine. 17(1-2). 29–35. 50 indexed citations

11.

Vuilleumier, Nicolas, et al.. (2010). Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity. Scandinavian Journal of Rheumatology. 39(6). 447–453. 49 indexed citations

12.

Vollenhoven, Ronald van, Sofia Ernestam, P. Geborek, et al.. (2009). Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. The Lancet. 374(9688). 459–466. 224 indexed citations

13.

Kopp, S, et al.. (2006). Interleukin‐1β influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis. Scandinavian Journal of Rheumatology. 35(3). 182–188. 11 indexed citations

14.

Kopp, Sigvard, et al.. (2005). Reduction of Temporomandibular Joint Pain after Treatment with a Combination of Methotrexate and Infliximab Is Associated with Changes in Synovial Fluid and Plasma Cytokines in Rheumatoid Arthritis. Cells Tissues Organs. 180(1). 22–30. 26 indexed citations

15.

Vollenhoven, Ronald van, et al.. (2003). Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. Arthritis Research & Therapy. 5(6). R347–51. 36 indexed citations

16.

Bratt, Johan, et al.. (2000). No effect of carvedilol on nitric oxide generation in phagocytes but modulation of production of superoxide ions. Biochemical Pharmacology. 59(8). 1007–1013. 19 indexed citations

17.

Heimbürger, Mikael, Gerd Lärfars, & Johan Bratt. (2000). Prednisolone inhibits cytokine-induced adhesive and cytotoxic interactions between endothelial cells and neutrophilsin vitro. Clinical & Experimental Immunology. 119(3). 441–448. 9 indexed citations

18.

Remahl, Ingela Nilsson, Elisabet Waldenlind, Johan Bratt, & Karl Ekbom. (2000). Cluster Headache Is Not Associated With Signs of a Systemic Inflammation. Headache The Journal of Head and Face Pain. 40(4). 276–282. 27 indexed citations

19.

Bratt, Johan & Jan Palmblad. (1997). Cytokine Activation of Human Endothelial Cells Stimulates Neutrophils To Become Cytotoxic: The Role of Nitric Oxide^a. Annals of the New York Academy of Sciences. 832(1). 163–169. 2 indexed citations

20.

Bratt, Johan, R. Lerner, B Ringertz, & Jan Palmblad. (1994). Lipoxin A4 Induces Neutrophil‐Dependent Cytotoxicity for Human Endothelial Cells. Scandinavian Journal of Immunology. 39(4). 351–354. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact